Previous Close | 51.02 |
Open | 51.57 |
Bid | 52.00 x 2200 |
Ask | 52.35 x 2200 |
Day's Range | 50.36 - 53.04 |
52 Week Range | 38.94 - 86.95 |
Volume | |
Avg. Volume | 1,079,293 |
Market Cap | 4.097B |
Beta (5Y Monthly) | 1.60 |
PE Ratio (TTM) | 13.92 |
EPS (TTM) | 3.76 |
Earnings Date | Nov 01, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 95.30 |
Subscribe to Yahoo Finance Plus to view Fair Value for CRSP
It's easy to see why investors might assume that early-stage gene-editing companies like CRISPR Therapeutics (NASDAQ: CRSP) are too inscrutable to approach. In fact, smart investors know (at least) three key things about this business, and you should too -- especially if you're considering purchasing shares sometime soon. CRISPR has a few partners, but its most important one by far is Vertex Pharmaceuticals (NASDAQ: VRTX).
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $50.47, moving -0.55% from the previous trading session.
Gene editing stocks present themselves as one of the more lucrative investments in the healthcare sector. Gene editing, a revolutionary take on the science of genetic engineering, has the potential to countless lives around the globe. By introducing genetic material into cells, scientists can correct genetic abnormalities in a way never seen before. With the potential for vast improvements, gene therapy and gene editing are promising modern biotechnology forms.InvestorPlace - Stock Market News,